Tallimustine
Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4].
Product Specifications
CAS Number
115308-98-0
Product Name Alternative
FCE 24517
UNSPSC
12352005
Target
Drug Derivative
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tallimustine.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(N(CCCl)CCCl)C=C1)NC2=CN(C)C(C(NC3=CN(C)C(C(NC4=CN(C)C(C(NCCC(N)=N)=O)=C4)=O)=C3)=O)=C2
Molecular Formula
C32H38Cl2N10O4
Molecular Weight
697.61
References & Citations
[1]Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38 (42) :14045-55. |[2]Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113 (4) :951-61. |[3]Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62 (2) :170-5.|[4]Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33 (2) :284-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
